^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Prolia (denosumab) (RANK ligand inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Adjuvant Denosumab treatment in early breast cancer: a systematic review and metaanalysis of randomized controlled clinical trials.
Published date:
11/22/2022
Excerpt:
In hormone receptor-positive/HER2 negative patients, denosumab significantly prolonged both DFS (HR 0.88; 95% CI 0.78-0.99, p=0.04) and BMFS (HR 0.83; 95% CI 0.71-0.97, p=0.02)...Findings from this meta-analysis validate the role of denosumab as a highly effective anti-resorptive agent. We provide robust evidence that its addition to standard anticancer treatment significantly improves survival outcomes in hormone receptor positive/HER2 negative early BC patients, suggesting that the implementation of denosumab use in combination with endocrine therapy in this patient population should be reconsidered.
